Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | FNTA | P49354 | 5/20 | 0.54 |
| ▸ | FNTB | P49356 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330623 | 1.00 | CA2 (0.55) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL8370132 | 0.87 | FNTA (0.64) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2329890 | 0.86 | ALDH1A1 (0.56) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2329886 | 0.86 | ALDH1A1 (0.56) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2330087 | 0.85 | FPR1 (0.57) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2334454 | 0.85 | FNTA (0.55) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2330092 | 0.85 | FPR1 (0.57) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2334449 | 0.85 | FNTA (0.55) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL8625049 | 0.85 | FNTA (0.59) | CA2CA1FNTAFNTBALDH1A1 | |
| SCHEMBL2330953 | 0.84 | ALDH1A1 (0.54) | CA2CA1FNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | CA2 2926/4885CA1 4797/4885FNTA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.